|Home||» Products||» Active Pharmaceutical Ingredients (API)||» TENELIGLIPTIN|
Being a reputed manufacturer and exporter, we are certain to offer our clients an appreciable range of TENELIGLIPTIN.
CAS Number : 760937-92-6
Molecular Formula: C22H30N6OS
Therapeutic Category: Antidiabetic
Mitsubishi Tanabe Pharma and launched in September 2012 by both Mitsubishi Tanabe Pharma and Daiichi Sankyo in Japan
In adults, 20 mg of Teneligliptin may be orally administered once daily. If this dosage is insufficient, the dosage is increased to 40 mg once daily.
Teneligliptin (Trade name Tenelia) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins"
Teneligliptin has unique J shaped or anchor locked domain structure because of which it has more potent inhibition of DPP 4 enzyme as compared to Sitagliptin and Vildagliptin
Teneligliptin significantly controls glycemic parameters with safety. No dose adjustment is required in renally impaired patients
Mechanism of Action:
Teneligliptin for the treatment of patients with Type 2 diabetes mellitus (T2DM). T2DM is a chronic disease characterized by hyperglycemia due to decreased secretion of insulin, the hormone that controls blood sugar levels, and resistance to the effects of insulin.
Teneligliptin consists of a considerably rigid J-shaped structure formed by five rings, four of which are directly connected to DPP -4 which provides strongest binding to DPP -4 enzymes as compared to other gliptins
Anchor lock domain, which binds to the S2 extensive subsite, increased the activity by 1500 -fold over the corresponding fragment that binds to S1 & S2 only.
Teneligliptin is well tolerated, safe, and significantly improves glycemic control in diabetic patients with ESRD.
Teneligliptin 20 mg is probably stronger than Vildagliptin 50 mg for dialysis patientsTeneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes.
Teneligliptin significantly improves the glycemic states in Diabetic ESRD patients
Teneligliptin exhibits beneficial effects on both oxidative stress and endothelial function in Japanese patients with type 2 diabetes and CKD
Improves glycemic states in patients switching from conventional Oral Anti-Diabetic drugs.